Ochsner High Grove

Futó vizsgálatok

• Toboroz

  Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab

  NCT05812807· 3. fázis· Forrás

• Toboroz

  Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease

  NCT05174169· 2/3. fázis· Forrás

• Fut, nem toboroz

  Testing the Use of Targeted Treatment (AMG 510) for KRAS G12C Mutated Advanced Non-squamous Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)

  NCT04625647· 2. fázis· Forrás

• Fut, nem toboroz

  Testing the Use of the Usual Chemotherapy Before and After Surgery for Removable Pancreatic Cancer

  NCT04340141· 3. fázis· Forrás

• Fut, nem toboroz

  Duloxetine to Prevent Oxaliplatin-Induced Peripheral Neuropathy in Patients With Stage II-III Colorectal Cancer

  NCT04137107· 2/3. fázis· Forrás

• Toboroz

  Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])

  NCT04267848· 3. fázis· Forrás

• Fut, nem toboroz

  NCI COVID-19 in Cancer Patients, NCCAPS Study

  NCT04387656· Forrás

• Fut, nem toboroz

  Testing the Addition of an Antibody to Standard Chemoradiation Followed by the Antibody for One Year to Standard Chemoradiation Followed by One Year of the Antibody in Patients With Unresectable Stage III Non-Small Cell Lung Cancer

  NCT04092283· 3. fázis· Forrás

• Fut, nem toboroz

  Targeted Treatment for RET Fusion-Positive Advanced Non-Small Cell Lung Cancer (A LUNG-MAP Treatment Trial)

  NCT04268550· 2. fázis· Forrás

• Fut, nem toboroz

  Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study

  NCT03793166· 3. fázis· Forrás

• Toboroz

  Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors

  NCT03866382· 2. fázis· Forrás

• Fut, nem toboroz

  A Study to Compare the Administration of Pembrolizumab After Surgery Versus Administration Both Before and After Surgery for High-Risk Melanoma

  NCT03698019· 2. fázis· Forrás

• Fut, nem toboroz

  Assessing the Ability of Combination Treatment With Venetoclax to Permit Time Limited Therapy in Chronic Lymphocytic Leukemia

  NCT03701282· 3. fázis· Forrás

• Toboroz

  Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer

  NCT03851445· 2/3. fázis· Forrás

• Toboroz

  Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change

  NCT03191149· 2. fázis· Forrás

• Fut, nem toboroz

  Testing MK-3475 (Pembrolizumab) After Surgery for Localized Muscle-Invasive Bladder Cancer and Locally Advanced Urothelial Cancer

  NCT03244384· 3. fázis· Forrás

• Fut, nem toboroz

  Combination Chemotherapy With or Without Atezolizumab in Treating Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair

  NCT02912559· 3. fázis· Forrás

• Toboroz

  Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia

  NCT03150693· 3. fázis· Forrás

• Fut, nem toboroz

  Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

  NCT02839707· 2/3. fázis· Forrás

• Fut, nem toboroz

  Nivolumab and Ipilimumab in Treating Patients With Rare Tumors

  NCT02834013· 2. fázis· Forrás

• Fut, nem toboroz

  Testing MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer

  NCT02954874· 3. fázis· Forrás

• Fut, nem toboroz

  Breast Cancer WEight Loss Study (BWEL Study)

  NCT02750826· 3. fázis· Forrás

• Fut, nem toboroz

  A Phase II/III Trial of Nivolumab, Ipilimumab, and GM-CSF in Patients With Advanced Melanoma

  NCT02339571· 2/3. fázis· Forrás

• Fut, nem toboroz

  Cisplatin and Etoposide Versus Temozolomide and Capecitabine in Patients With Advanced Poorly Differentiated (G3) Non-Small Cell Gastrointestinal Neuroendocrine Carcinomas

  NCT02595424· 2. fázis· Forrás

• Fut, nem toboroz

  Platinum in Treating Patients With Residual Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy

  NCT02445391· 3. fázis· Forrás

• Fut, nem toboroz

  Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma

  NCT02224781· 3. fázis· Forrás

• Fut, nem toboroz

  Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

  NCT02465060· 2. fázis· Forrás

• Fut, nem toboroz

  Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer

  NCT02488967· 3. fázis· Forrás

• Fut, nem toboroz

  Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)

  NCT02201992· 3. fázis· Forrás

• Fut, nem toboroz

  Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial)

  NCT02193282· 3. fázis· Forrás

• Fut, nem toboroz

  Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)

  NCT02194738· Forrás

• Fut, nem toboroz

  Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia

  NCT02003222· 3. fázis· Forrás

• Fut, nem toboroz

  S0820, Adenoma and Second Primary Prevention Trial

  NCT01349881· 3. fázis· Forrás

Egyszerre toboroz

Hány vizsgálat toboroz itt egyszerre ugyanarra az indikációra. Darabszám, nem értékelés.

• Tripla negatív emlőrák1 toboroz
• Vastagbélrák1 toboroz

Kutatók

Ide még nem kötődik kutató.

Lezárt vizsgálatok

• Lezárult

  Combination Treatment (Talazoparib Plus Avelumab) for Stage IV or Recurrent Non-Squamous Non-Small Cell Lung Cancer With STK11 Gene Mutation (A LUNG-MAP Treatment Trial)

  NCT04173507· 2. fázis· Forrás

• Lezárult

  Ramucirumab and Pembrolizumab Versus Standard of Care in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Non-Match Treatment Trial)

  NCT03971474· 2. fázis· Forrás

• Lezárult

  Rucaparib in Treating Patients With Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)

  NCT03845296· 2. fázis· Forrás

• Lezárult

  Gemcitabine Hydrochloride and Cisplatin With or Without Nab-Paclitaxel in Treating Patients With Newly Diagnosed Advanced Biliary Tract Cancers

  NCT03768414· 3. fázis· Forrás

• Lezárult

  S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery

  NCT03365882· 2. fázis· Forrás

• Lezárult

  Cisplatin With or Without Veliparib in Treating Patients With Recurrent or Metastatic Triple-Negative and/or BRCA Mutation-Associated Breast Cancer With or Without Brain Metastases

  NCT02595905· 2. fázis· Forrás